ABVC News & Events

ABVC BioPharma announced the receipt of a $200,000 cash payment from OncoX BioPharma as part of its strategic licensing agreement for certain oncology-related products; this payment marks the first installment of $5M in potential licensing fees from OncoX. With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and Rgene Corporation are each eligible to receive up to 10M OncoX shares, $5M cash payment, and royalties up to $50M after the product launches. The OncoX licensing agreement highlights both companies' commitment to advancing breakthrough therapies in oncology.

Reports Q3 revenue $389,276 vs $15,884 last year. Improved Cash Position: The Company's cash and cash equivalents reached $137,344 as of September 30, 2024, up from $60,155 at the end of 2023. Through strategic financing and operational efficiencies, ABVC has strengthened its liquidity to support upcoming anticipated clinical milestones and expansion efforts.

ABVC BioPharma announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner's belief in our mission. ABVC has received 23M AiBtl shares as part of the first milestone of the licensing fees and will obtain royalties up to $100M after the product launches. The payment, tied to ABVC's psychiatric disorder pipeline, which includes treatments for Major Depressive Disorder and Attention Deficit Hyperactivity Disorder, is part of a broader agreement with AiBtl BioPharma. The MDD and ADHD pipeline, valued at $667M by third-party evaluators, continues to gain momentum as both companies advance their collaborative efforts towards discussion with big pharma for out-licensing and initiating the plan for the GAP-certified temperature-controlled farm.